KRAS and familial pancreatic carcinoma: In a study in which 2483 patients with pancreatic cancer were analysed, 11% of the tumours had nonmutated KRAS, and these tumours had a better prognosis and characteristics that favoured the administration of immunotherapy (higher percentage of microsatellite instability, greater tumour mutational burden, and greater infiltration of CD8+ inflammatory cells).